Syntrix Wins $96M Verdict Against Illumina In DNA Patent Suit

Law360, Los Angeles (March 14, 2013, 10:47 PM EDT) -- A federal jury on Thursday returned a verdict for $96 million in favor of biotechnology research firm Syntrix Biosystems Inc., finding that Illumina Inc. has infringed and induced others to infringe a patent covering DNA technology held by Syntrix.

Thursday’s jury verdict marks an end to the patent suit filed by Syntrix in November 2010 alleging that Illumina willfully infringed the patent, misappropriated trade secrets and breached a contract the companies struck when they were considering a partnership in 2000.

At trial, Syntrix pursued claims of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.